Skip to main content

Study Looks at Impact of Peritoneal Dialysis on Thyroid Function

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 23, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Sept. 23, 2024 -- Patients undergoing peritoneal dialysis (PD) have significantly higher thyroxine (T4) concentrations than hemodialysis (HD) patients and higher free T4 (FT4) concentrations at 12 and 24 months, according to a study published online Sept. 7 in Seminars in Dialysis.

Jelić Pranjić Ita, M.D., from the University Hospital Center Rijeka in Croatia, and colleagues conducted a prospective single-center study to examine thyroid function in 18 PD patients during a 24-month period. Data were compared to those from concurrently treated HD patients.

The researchers found that some of the PD patients had elevated thyroid-stimulating hormone levels initially, which normalized during follow-up, despite longer duration of dialysis. PD patients had significantly higher T4 concentrations at baseline and higher FT4 concentrations at 12 and 24 months compared with HD patients. At baseline and at 12 and 24 months, free triiodothyronine (FT3) levels were significantly higher; after the beginning of the study, T3 levels were within the reference interval. In PD patients, there was a positive association between T4 levels and 24-hour diuresis after 12 months.

"PD's continuous nature offers the benefit of better preservation of residual kidney function and gradual toxin removal," the authors write. "However, the complete precise factors influencing potential differences in survival have not been fully elucidated."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

Global Prevalence of Congenital Heart Disease at High Altitude ~9 Percent

THURSDAY, Sept. 26, 2024 -- The global prevalence of congenital heart disease (CHD) at high altitude is 8.97 percent, according to the results of a review presented at the...

Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer

THURSDAY, Sept. 26, 2024 -- Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other nonkeratinocyte skin cancers...

Federal Government to Offer More Free COVID-19 Tests

WEDNESDAY, Sept. 25, 2024 -- The U.S. government is offering another round of free COVID-19 tests, which will be available by the end of September. "U.S. households will be...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.